Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KB304 · 1 trial · 3 indications
Treatment related adverse events as assessed by CTCAE
| Arm | Type | Description |
|---|---|---|
| KB304 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| KB304 | BIOLOGICAL | Genetically modified herpes simplex type 1 virus |
| 0.9% Normal Saline (NS) | DRUG | Placebo |
Inclusion Criteria: * Female in good general health, as determined by the Investigator, aged ≥18 and ≤75 at the time of consent. * Presence of moderate to severe dynamic wrinkles in the décolleté Target Area, as determined by the Investigator on the JDWS. * A Fitzpatrick skin phototype score of I-I...
KB304 is an investigational monoclonal antibody being developed for the treatment of wrinkles in the décolletage, also known as the chest area. It is being studied in women with décolleté wrinkles and pigmentation. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
KB304 targets COL3A1 and ELN, which are proteins associated with collagen and elastin production in the skin. By targeting these molecular pathways, the drug is intended to address wrinkles in the décolletage area. This mechanism is being evaluated in an early-stage clinical trial for safety and efficacy.
KB304 is being developed by Krystal Biotech, Inc., a biopharmaceutical company. The company is conducting clinical research on this investigational drug for dermatological use. Krystal Biotech is publicly traded under the ticker symbol KRYS on the stock market.
KB304 is in Phase 1 clinical development. The drug is being studied in an early-stage trial to assess its safety and tolerability in women with wrinkles in the décolletage. As an investigational agent, KB304 has not yet received approval from the U.S. Food and Drug Administration or other regulatory bodies.
KB304 is being evaluated in a Phase 1 clinical trial registered as NCT06724900. This study is assessing the treatment of wrinkles in women and is currently active but not recruiting participants. The trial is enrolling 19 healthy female volunteers aged 18 years and older in the United States.
KB304 is a distinct investigational monoclonal antibody developed by Krystal Biotech. It is being studied specifically for wrinkles in the décolletage, a condition that differs from facial wrinkles. The drug's mechanism targets COL3A1 and ELN, which may differentiate it from other wrinkle treatments, though comparative data is not yet available.